2-methyl-5-methoxypyridin-3-amine | 1104455-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-5-methoxypyridin-3-amine
• 英文别名: 5-Methoxy-2-methylpyridin-3-amine
• CAS: 1104455-29-9
• 化学式: C₇H₁₀N₂O
• mdl: MFCD18250733
• 分子量: 138.169
• InChiKey: NIZHNEQMBILCQO-UHFFFAOYSA-N

物化性质

• 沸点：
  290.0±35.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基-2-氯-5-甲氧基吡啶 、 三甲基环三硼氧烷 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 0.5h， 以100%的产率得到2-methyl-5-methoxypyridin-3-amine
  参考文献：
  名称：

  [EN] 2,4-DIAMINO-PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE 2,4-DIAMINO-PYRIMIDINE

  摘要：

  本发明涉及式(I)化合物，或其药用可接受盐，其中R1、Q、R3和R4如描述中定义。本发明还涉及制备此类化合物的方法、包含它们的药物组合物以及它们在制造用作抗增殖剂的药物中的应用，用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病。

  公开号：

  WO2009010794A1

文献信息

• NOVEL PYRIMIDINE DERIVATIVES 965
  申请人：Barlaam Bernard Christophe

  公开号：US20090054428A1

  公开（公告）日：2009-02-26

  The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R 1 , Q, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.

  该发明涉及公式I的化合物，或其药学上可接受的盐，其中R1，Q，R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法，包含它们的制药组合物以及它们在制造用于作为抗增殖剂用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病的药物的用途。
• BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Shionogi & Co., Ltd

  公开号：EP3527568A1

  公开（公告）日：2019-08-21

  Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. A compound represented by Formula (I): wherein Z1 is C(R4) or the like; R4 is a hydrogen atom or the like; Z2 is C(R5a)(R5a') or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then R5a' is absent; R5a and R5a' are each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Y1 is O or the like; R2a is a group represented by the formula: -(C(R2a')(R2b'))n-R1; R2b is a hydrogen atom or the like; R2a' and R2b' is each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.

  本文提供了一种对 P2X7 受体具有拮抗活性的新型化合物，以及一种对 P2X7 受体具有拮抗活性的药物组合物。由式（I）代表的化合物： 其中Z1是C(R4)或类似物；R4是氢原子或类似物；Z2是C(R5a)(R5a')或类似物；虚线表示键的存在或不存在；当虚线表示键的存在时，则R5a'不存在；R5a和R5a'各自独立地是氢原子或类似物；环Q是取代或未取代的5元非芳杂环或类似物；Y1是O或类似物；R2a是由式表示的基团：-(C(R2a')(R2b'))n-R1； R2b 是氢原子或类似物； R2a'和 R2b'各自独立地是氢原子或类似物； R1 是取代或未取代的芳香族碳环或类似物； X 是 N(R7a)或类似物；R7a 是氢原子或类似物；R3 是取代或未取代的芳香族羰基或类似物；n 是 0 至 4 的整数；和 m 是 0 至 4 的整数，或其药学上可接受的盐。
• Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
  申请人：Shionogi & Co., Ltd.

  公开号：US11066409B2

  公开（公告）日：2021-07-20

  Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

  本文提供了一种对 P2X7 受体具有拮抗活性的新型化合物，以及一种对 P2X7 受体具有拮抗活性的药物组合物。该化合物由式（I）表示： 其中符号在说明书中定义，或其药学上可接受的盐。
• BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Shionogi & Co., Ltd.

  公开号：US20200048257A1

  公开（公告）日：2020-02-13

  Provided are a novel compound having an antagonistic activity for the P2X 7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X 7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.